TP53 and ovarian carcinoma: One patient with germline BRCA1 mutant and platinum-refractory, PARP inhibitor-resistant ovarian cancer with a somatic Y220C TP53 mutation had RECIST partial response for 6 months and 8 other patients in part B had stable disease [137].